12:00 AM
 | 
Oct 15, 2012
 |  BC Week In Review  |  Company News  |  Deals

Diamyd Medical, Periphagen Holdings deal

Diamyd will sell its U.S. subsidiary Diamyd Inc. to Periphagen for $1 and a holding of 10% in Periphagen. As part of the deal, Periphagen will acquire IP rights to Diamyd's Nerve Targeting Drug...

Read the full 147 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >